• About us
• Contact

Advertisement

Person › Details

Arie Belldegrun (Kite Pharma Inc.)

Belldegrun, Arie (Allogene 201806 Executive Chairman before Kite Pharma CEO)

 

	Organisation	Kite Pharma Inc.
	Group	Gilead Sciences (Group)
	Product	CAR T-cell therapy product
	Product 2	eACT™ (engineered autologous T cell therapy)

Record changed: 2024-08-08

Advertisement

More documents for Arie Belldegrun

• [1] Symbiotic Capital LLC. (8/6/24). "Press Release: Symbiotic Capital, a First-of-its-Kind Life Science Credit Firm, Launches with More than $600 Million Raised". Los Angeles, CA....
• [2] Ginkgo Bioworks Inc.. (5/11/21). "Press Release: Ginkgo Bioworks to Become a Public Company and Expand its Leading Platform for Cell Programming". Boston, MA & Los Angeles, CA....
• [3] Neogene Therapeutics, Inc.. (9/14/20). "Press Release: Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies". New York, NY & Amsterdam....
• [4] Vida Ventures. (8/1/19). "Press Release: Vida Ventures Closes $600 Million Vida II Fund to Support Life Science Innovation". Boston, MA....
• [5] UroGen Pharma Ltd.. (1/3/19). "Press Release: UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer". New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.